{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:08:49Z","timestamp":1790885329370,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40265-024-02067-8","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T18:02:29Z","timestamp":1718906549000},"page":"811-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Effects of Oral ALZ-801\/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-6231","authenticated-orcid":false,"given":"John A.","family":"Hey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Abushakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Hort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels D.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Sheardova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kesslak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijo","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean F.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"2067_CR1","unstructured":"Alzheimer\u2019s Association Facts and Figures. 2024. https:\/\/www.alz.org\/media\/Documents\/alzheimers-facts-and-figures.pdf."},{"issue":"5123","key":"2067_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133. https:\/\/doi.org\/10.1126\/science.8346443.","journal-title":"Science"},{"key":"2067_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.med.47.1.387","volume":"47","author":"AD Roses","year":"1996","unstructured":"Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer\u2019s disease. Annu Rev Med. 1996;47:387\u2013400. https:\/\/doi.org\/10.1146\/annurev.med.47.1.387.","journal-title":"Annu Rev Med"},{"key":"2067_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000334607","volume":"38","author":"A Ward","year":"2012","unstructured":"Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of Apolipoprotein E4 genotype and homozygotes (APOE e4\/4) among patients diagnosed with alzheimer\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38:1\u201317. https:\/\/doi.org\/10.1159\/000334607.","journal-title":"Neuroepidemiology"},{"key":"2067_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"2067_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367\u201385. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2351.","journal-title":"Alzheimers Dement"},{"key":"2067_CR7","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324. https:\/\/doi.org\/10.1093\/brain\/awad188.","journal-title":"Brain"},{"key":"2067_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, et al. Detection and management of amyloid- related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9:211\u201320. https:\/\/doi.org\/10.14283\/jpad.2022.21.","journal-title":"J Prev Alzheimers Dis."},{"key":"2067_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1742-2094-1-24","volume":"1","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against A\u03b2 in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm. 2004;1:24. https:\/\/doi.org\/10.1186\/1742-2094-1-24.","journal-title":"J Neuroinflamm"},{"key":"2067_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease\u2014one peptide, two pathways. Nat Rev Neurol. 2020;16:30\u201342. https:\/\/doi.org\/10.1038\/s41582-019-0281-2.","journal-title":"Nat Rev Neurol"},{"key":"2067_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp-2013-306485","volume":"85","author":"K Rannikm\u00e4e","year":"2014","unstructured":"Rannikm\u00e4e K, Kalaria RN, Greenberg SM, Chui HC, Schmitt FA, Samarasekera N, et al. APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85:300\u20135. https:\/\/doi.org\/10.1136\/jnnp-2013-306485.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2067_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 2022;79:228\u201343. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5216.","journal-title":"JAMA Neurol"},{"key":"2067_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.862369","volume":"13","author":"CG Withington","year":"2022","unstructured":"Withington CG, Turner RS. Amyloid-related imaging abnormalities with anti- amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease. Front Neurol. 2022;13: 862369. https:\/\/doi.org\/10.3389\/fneur.2022.862369.","journal-title":"Front Neurol"},{"issue":"1","key":"2067_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95. https:\/\/doi.org\/10.1186\/s13195-020-00663-w.","journal-title":"Alzheimers Res Ther."},{"issue":"12","key":"2067_CR15","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.3390\/ijms22126355","volume":"22","author":"M Tolar","year":"2021","unstructured":"Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci. 2021;22(12):6355. https:\/\/doi.org\/10.3390\/ijms22126355.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2067_CR16","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/ijms25052727","volume":"25","author":"M Tolar","year":"2024","unstructured":"Tolar M, Hey JA, Power A, Abushakra S. The single toxin origin of Alzheimer\u2019s disease and other neurodegenerative disorders enables targeted approach to treatment and prevention. Int J Mol Sci. 2024;25(5):2727. https:\/\/doi.org\/10.3390\/ijms25052727.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2067_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","volume":"31","author":"P Kocis","year":"2017","unstructured":"Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, et al. Elucidating the abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer\u2019s disease: integrating molecular analytical Methods, pharmacokinetic and clinical data. CNS Drugs. 2017;31(6):495\u2013509. https:\/\/doi.org\/10.1007\/s40263-017-0434-z.","journal-title":"CNS Drugs"},{"issue":"9","key":"2067_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","volume":"32","author":"JA Hey","year":"2018","unstructured":"Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnalek M, et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs. 2018;32(9):849\u201361. https:\/\/doi.org\/10.1007\/s40263-018-0554-0.","journal-title":"CNS Drugs"},{"issue":"10","key":"2067_CR19","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1021\/acs.jctc.9b00599","volume":"15","author":"C Liang","year":"2019","unstructured":"Liang C, Savinov SN, Fejzo J, Eyles SJ, Chen J. Modulation of amyloid-beta42 conformation by small molecules through nonspecific binding. J Chem Theory Comput. 2019;15(10):5169\u201374. https:\/\/doi.org\/10.1021\/acs.jctc.9b00599.","journal-title":"J Chem Theory Comput"},{"issue":"3","key":"2067_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","volume":"57","author":"JA Hey","year":"2018","unstructured":"Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer\u2019s disease. Clin Pharmacokinet. 2018;57(3):315\u201333. https:\/\/doi.org\/10.1007\/s40262-017-0608-3.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2067_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14283\/jpad.2016.115","volume":"3","author":"S Abushakra","year":"2016","unstructured":"Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, et al. Clinical benefits of tramiprosate in Alzheimer\u2019s disease are associated with higher number of APOE4 alleles: the \u201cAPOE4 gene-dose effect.\u201d J Prev Alz Dis. 2016;3(4):219\u201328. https:\/\/doi.org\/10.14283\/jpad.2016.115.","journal-title":"J Prev Alz Dis."},{"issue":"3","key":"2067_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2017.26","volume":"4","author":"S Abushakra","year":"2017","unstructured":"Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, et al. Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer\u2019s disease suggest disease modification potential. J Prev Alzeimers Dis. 2017;4(3):149\u201356. https:\/\/doi.org\/10.14283\/jpad.2017.26.","journal-title":"J Prev Alzeimers Dis."},{"key":"2067_CR23","doi-asserted-by":"publisher","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","volume":"32","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid peptide. J Neurosci. 2012;32:15181\u201392. https:\/\/doi.org\/10.1523\/JNEUROSCI.1542-12.2012.","journal-title":"J Neurosci"},{"key":"2067_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","volume":"34","author":"AS Fleisher","year":"2013","unstructured":"Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, et al. Apolipoprotein E \u03b54 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1\u201312. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.04.017.","journal-title":"Neurobiol Aging"},{"key":"2067_CR25","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1939\u201349. https:\/\/doi.org\/10.1001\/jama.2015.4669.","journal-title":"JAMA"},{"issue":"5","key":"2067_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaque-Alcazar L, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med. 2024;30(5):1284\u201391. https:\/\/doi.org\/10.1038\/s41591-024-02931-w.","journal-title":"Nat Med"},{"key":"2067_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimer\u2019s Dement."},{"key":"2067_CR28","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470\u201381. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.010.","journal-title":"Alzheimers Dement"},{"key":"2067_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01382-x.","journal-title":"Nat Med"},{"key":"2067_CR30","unstructured":"Jack CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer\u2019s Association Workgroup. 2023."},{"issue":"16","key":"2067_CR31","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci Adv. 2020;6(16):eaaz2387. https:\/\/doi.org\/10.1126\/sciadv.aaz2387.","journal-title":"Sci Adv"},{"issue":"4","key":"2067_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","volume":"78","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodr\u00edguez J, Snellman A, et al. Longitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer\u2019s disease. JAMA Neurol. 2021;78(4):396\u2013406. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4986.","journal-title":"JAMA Neurol"},{"key":"2067_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/s1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333. https:\/\/doi.org\/10.1016\/s1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2067_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2022","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Zimmer ER, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid-PET vs with tau-PET. JAMA Neurol. 2022;80(2):188\u201399. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485.","journal-title":"JAMA Neurol"},{"issue":"2","key":"2067_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30.","journal-title":"J Prev Alzheimers Dis."},{"key":"2067_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"G McKhann","year":"2011","unstructured":"McKhann G, Knopman DS, Chertkow H, Hymann B, Jack CR, Kawas C, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"2067_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimer\u2019s Dement."},{"key":"2067_CR38","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1002\/alz.13455","volume":"19","author":"K Blennow","year":"2023","unstructured":"Blennow K, Galasko D, Perneczky R, Quevenco FC, van der Flier WM, Akinwonmi A, et al. The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:5805\u201316. https:\/\/doi.org\/10.1002\/alz.13455.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2067_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12117","volume":"6","author":"S Abushakra","year":"2020","unstructured":"Abushakra S, Porsteinsson AP, Sabbagh M, Bracoud L, Schaerer J, Power A, et al. APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. Alzheimers Dement (N Y). 2020;6(1): e12117. https:\/\/doi.org\/10.1002\/trc2.12117.","journal-title":"Alzheimers Dement (N Y)."},{"key":"2067_CR40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.000000000020355","author":"S Abushakra","year":"2023","unstructured":"Abushakra S, Mandelbaum R, Barakos J, Scheltens P, Porsteinsson AP, Watson D, et al. Prevalence of amyloid-related imaging abnormalities in APOE4\/4 homozygotes with early Alzheimer\u2019s disease (AD): baseline findings from ongoing clinical trials of the oral anti-amyloid agent ALZ-801 (valiltramiprosate) (P5\u20136.003). Neurology. 2023. https:\/\/doi.org\/10.1212\/WNL.000000000020355.","journal-title":"Neurology"},{"key":"2067_CR41","volume-title":"Wechsler adult intelligence scale-revised manual","author":"D Wechsler","year":"1981","unstructured":"Wechsler D. Wechsler adult intelligence scale-revised manual. New York: The Psychological Corporation; 1981."},{"key":"2067_CR42","volume-title":"Neuropsychological assessment","author":"MD Lezak","year":"2004","unstructured":"Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment. 4th ed. New York: Oxford University Press; 2004.","edition":"4"},{"key":"2067_CR43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/geronj\/33.2.232","volume":"33","author":"TA Salthouse","year":"1978","unstructured":"Salthouse TA. The role of memory in the age decline in digit-symbol substitution performance. J Gerontol. 1978;33:232\u20138. https:\/\/doi.org\/10.1093\/geronj\/33.2.232.","journal-title":"J Gerontol"},{"issue":"3","key":"2067_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"2067_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harveyet DJ, et al. Alzheimer\u2019s disease neuroimaging initiative (ADNI): clinical characterization. Neurology. 2010;74:201\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e3181cb3e25.","journal-title":"Neurology"},{"key":"2067_CR46","volume-title":"Effects of oral ALZ-801 on plasma and MRI biomarkers in APOE4 carriers with Early AD: 52-week analysis from Phase 2 biomarker study","author":"S Abushakra","year":"2022","unstructured":"Abushakra S. Effects of oral ALZ-801 on plasma and MRI biomarkers in APOE4 carriers with Early AD: 52-week analysis from Phase 2 biomarker study. San Francisco: Clinical Trials on Alzheimer\u2019s Disease (CTAD); 2022."},{"issue":"8","key":"2067_CR47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O'Bryant","year":"2008","unstructured":"O\u2019Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer\u2019s research consortium study. Arch Neurol. 2008;65(8):1091\u20135. https:\/\/doi.org\/10.1001\/archneur.65.8.1091.","journal-title":"Arch Neurol"},{"key":"2067_CR48","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1212\/01.wnl.0000172913.88973.0d","volume":"65","author":"D Mungas","year":"2005","unstructured":"Mungas D, Harvey D, Reed BR, Jagust WJ, DeCarli C, Beckett L, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology. 2005;65:565\u201371. https:\/\/doi.org\/10.1212\/01.wnl.0000172913.88973.0d.","journal-title":"Neurology"},{"key":"2067_CR49","doi-asserted-by":"publisher","first-page":"418","DOI":"10.14283\/jpad.2023.68","volume":"10","author":"D Angioni","year":"2023","unstructured":"Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, et al. Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU\/US CTAD Task Force. J Prev Alzheimers Dis. 2023;10:418\u201325. https:\/\/doi.org\/10.14283\/jpad.2023.68.","journal-title":"J Prev Alzheimers Dis."},{"issue":"8","key":"2067_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"J Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway J, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain - implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457\u201370. https:\/\/doi.org\/10.1038\/nrneurol.2015.119.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2067_CR51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","volume":"5","author":"AE Roher","year":"2009","unstructured":"Roher AE, Esh CL, Kokjohn TA, Casta\u00f1o EM, Van Vickle GD, Kalback WM, et al. A\u03b2 peptides in human plasma and tissues and their significance for Alzheimer\u2019s disease. Alzheimers Dement. 2009;5(1):18\u201329. https:\/\/doi.org\/10.1016\/j.jalz.2008.10.004.","journal-title":"Alzheimers Dement"},{"key":"2067_CR52","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2023.04.003","volume":"28","author":"F Gervais","year":"2007","unstructured":"Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble A\u03b2 peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28:537\u201347. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2023.04.003.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2067_CR53","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/alz.13539","volume":"20","author":"PM Cogswell","year":"2024","unstructured":"Cogswell PM, Lundt ES, Therneau TM, Wiste HJ, Graff-Radford J, Algeciras-Schimnich A, et al. Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET. Alzheimers Dement. 2024;20(2):1225\u201338. https:\/\/doi.org\/10.1002\/alz.13539.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2067_CR54","doi-asserted-by":"publisher","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","volume":"96","author":"R La Joie","year":"2021","unstructured":"La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology. 2021;96(5):e650\u201361. https:\/\/doi.org\/10.1212\/WNL.0000000000011270.","journal-title":"Neurology"},{"issue":"6","key":"2067_CR55","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"3","key":"2067_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"JL Cummings","year":"2023","unstructured":"Cummings JL, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"J Prev Alzheimers Dis."},{"key":"2067_CR57","doi-asserted-by":"publisher","unstructured":"Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, et al. Analysis of cerebrospinal fluid, plasma \u03b2-amyloid biomarkers and cognition from 2-year phase 2 trial evaluating oral ALZ-801\/valiltramiprosate in APOE4 carriers with early Alzheimer\u2019s disease using quantitative systems pharmacology model. Drugs 2024;84. https:\/\/doi.org\/10.1007\/s40265-024-02068-7.","DOI":"10.1007\/s40265-024-02068-7"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02067-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02067-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02067-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T10:24:58Z","timestamp":1722335098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02067-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2067"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02067-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"14 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by Alzheon, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.A.H., S.A.S., P.K., A.A., J.P., J.F.S., A.P., and M.T. are employees of Alzheon Inc. and hold stocks or stock options in Alzheon Inc. L.S. and X.Z. are employees of Wuxi Apptec that provides statistical contracting services to Alzheon Inc. K.B., E.M.R., J.H., and K.S. are scientific advisors to Alzheon Inc. and hold stocks or stock options in Alzheon Inc. N.D.P. is an investigator in the phase 2 and phase 3 studies of ALZ-801.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol was approved by the assigned ethics committees (EC) in the Netherlands and in Czech Republic and by some institutional EC in the Czech Republic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All subjects and their partners, caregivers, or legal representatives signed informed consent before participation in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"ADNI datasets are publicly available at the website http\/\/ADNI.LONI.USC.edu. The ALZ-801 data are proprietary to Alzheon Inc.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"J.A.H., S.A.S., and A.P. created the study concept and design; K.B., E.M.R., J.H., and K.S. provided advice on study design or biomarker selection; S.A.S., P.K., J.A.H., A.P., J.P., and L.S. wrote the protocol; S.A.S. and J.A.H. selected the study sites and oversaw the study conduct; N.D.P. provided oversight of study enrollment and conduct; S.A.S. and P.K. oversaw subject safety; J.A.H., J.P., and J.F.S. oversaw the laboratory and biomarker sample workstream and drug supply; S.A.S. and J.A.H. wrote the manuscript; S.A.S., J.A.H., A.P., P.K., A.A., P.K., J.F.S., L.S., X.Z., and M.T. reviewed the manuscript and provided substantial edits. All authors have read and approve the final submitted manuscript and agree to be accountable for the work","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}